Clinical Validation of the Cervista HPV HR Test According to the International Guidelines for Human Papillomavirus Test Requirements for Cervical Cancer Screening

Aniek Boers, Rong Wang, Lorian Slagter-Menkema, Bettien M. van Hemel, Hilde Ghyssaert, Ate G. J. van der Zee, G. Bea A. Schuurs-Wisman, Ed Schuuring*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

18 Citations (Scopus)
331 Downloads (Pure)

Abstract

This study demonstrates that both the clinical sensitivity and specificity of the Cervista HPV HR test for high-risk human papillomavirus (HPV) detection are not inferior to those of the Hybrid Capture 2 (HC2) test. The intra- and interlaboratory reproducibilities of Cervista were 92.0% (kappa, 0.83) and 90.4% (kappa, 0.80), respectively. The Cervista HPV HR test fulfills all the international HPV test requirements for cervical primary screening purposes.

Original languageEnglish
Pages (from-to)4391-4393
Number of pages3
JournalJournal of Clinical Microbiology
Volume52
Issue number12
DOIs
Publication statusPublished - Dec-2014

Keywords

  • HIGH-RISK HPV
  • HYBRID CAPTURE 2
  • CYTOLOGY
  • WOMEN
  • PERFORMANCE
  • ASSAY
  • DNA
  • EXPERIENCE
  • AGE

Cite this